Key considerations when preparing patients with ALL for CAR T-cell therapy

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Key considerations when preparing patients with ALL for CAR T-cell therapy

Listen for free

View show details

About this listen

During the ALL Hub Steering Committee meeting, André Baruchel chaired a discussion on “What are the key considerations when preparing patients with ALL for CAR T-cell therapy ?”, featuring Andrea Biondi, Anita Rijneveld, and José María Ribera.

The discussion topics included:

Key considerations when selecting patients: stable disease, degree of antigen expression, burden of bone marrow disease, and number of circulating tumor blasts
Bridging therapy and lymphodepletion considerations
The impact of prior exposure to blinatumomab and inotuzumab on CAR T-cell outcomes
Indications for the use of tisagenlecleucel in pediatric ALL
Indications for the use of brexucabtagene autoleucel in adult ALL

Hosted on Acast. See acast.com/privacy for more information.

No reviews yet